Sunday, October 12, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Reiterates Positive Outlook on Celsius Holdings with Increased Price Target

Elaine Mendonca by Elaine Mendonca
March 14, 2024
in Breaking News
0
Beverages Industry Markets and money
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

Sean McGowan, an analyst at Roth MKM, has reiterated his positive outlook on Celsius Holdings (NASDAQ: CELH) by maintaining a Buy rating and increasing the price target to $105, up from $90. The company’s stock closed at $91.07 on March 14, 2024, marking a 6.75% increase from the previous day and a remarkable 234.66% surge over the past year.

Celsius Holdings specializes in developing, processing, marketing, distributing, and selling functional beverages and liquid supplements on a global scale. While some analysts, like Gerald Pascarelli from Wedbush, share a bullish sentiment with a Buy rating and a price target of $75.00, opinions on the stock vary across the board.

It’s worth noting that analyst ratings serve as indicators of market sentiment and future projections rather than direct financial advice or recommendations.

Celsius Holdings Inc. (CELH) Sees Slight Decline in Stock Performance on March 14, 2024: What Investors Need to Know

On March 14, 2024, Celsius Holdings Inc. (CELH) saw a slight decline in its stock performance, with shares decreasing by $1.67, or 1.74%, since the previous market close. Despite this drop, CELH is still trading near the top of its 52-week range and above its 200-day simple moving average, indicating strong overall performance.

Investors may want to consider various factors when evaluating CELH’s stock performance, such as the company’s financial health, market trends, and industry competition. Additionally, conducting thorough research and analysis can help investors make informed decisions about buying, selling, or holding onto CELH shares.

Overall, while CELH experienced a slight decline in its stock price on March 14, 2024, the company’s strong position relative to its 52-week range and moving average suggests that it may still have potential for growth in the future. As always, investors should exercise caution and consider their own risk tolerance and investment goals before making any decisions in the stock market.

Celsius Holdings Inc. Reports Impressive Financial Results for 2023, Revenue Up 101.65%: Whats Next for CELH Stock?

On March 14, 2024, Celsius Holdings Inc. (CELH) reported impressive financial results for the past year, with total revenue reaching $1.32 billion, representing a significant increase of 101.65% compared to the previous year. Net income for CELH also saw a substantial increase over the past year, reaching $226.80 million, a growth of 221.1% compared to the previous year. Earnings per share (EPS) for CELH stood at $0.77 for the past year, reflecting a notable increase of 187.67% compared to the previous year. Overall, CELH’s financial performance over the past year has been strong, with significant growth in total revenue, net income, and earnings per share. Investors may view the company’s consistent revenue growth positively, although the slight decrease in net income and EPS since the last quarter may raise some concerns. It will be interesting to see how CELH stock performs in the coming days following these financial results. Investors will likely closely monitor any updates from the company and industry trends to assess the stock’s potential for future growth.

Tags: CELH
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
NFT projects

Exploring the Rise of NFT Projects: How Cultural Themes Are Reshaping the Crypto Landscape

Finance_ projections

UBS Downgrades Tesla Stock Lowers Price Target

Finance_Commercial (2)

Analyst Reaffirms Positive Outlook on International General Insurance with Outperform Rating

Recommended

Home Construction Trading online

PulteGroup Reports Positive Earnings Surprise in Q4 2022

2 years ago
Lam Research Stock

Semiconductor Sector Sees New Leveraged ETF Targeting Lam Research

2 months ago
Orion Office REIT Stock

Defying Sector Headwinds: Orion Office REIT’s Remarkable Ascent

1 month ago
Finance_Commercial (2)

Embecta Corps Positive Financial Results Overshadowed by Disappointing Guidance

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BigBear.ai BioNTech Broadcom Coinbase Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Precision BioSciences Stock Surges on Gene-Editing Breakthroughs

Hydrogen Sector’s Crossroads: Nel ASA Navigates Industry Retreat and Government Push

Norwegian Car Carrier Faces Mounting Headwinds as Shares Slide

Defense Stock Paradox: Record Orders Trigger Share Price Retreat

Idorsia Secures Strong Investor Backing in Oversubscribed Share Offering

Vulcan Energy Shares Face Pressure Following Shareholder Approval

Trending

Ebix Stock
Blockchain

Ebix Pursues Dual-Pronged Growth Strategy

by Robert Sasse
October 12, 2025
0

Ebix has launched two significant strategic moves that demonstrate the company's focused approach to strengthening its market...

India Globalization Capital Stock

Shareholder Confidence Boosts IGC Pharma’s Alzheimer’s Research

October 12, 2025
Allovir Inc Stock

Allovir’s Corporate Metamorphosis: A New Beginning as Kalaris Therapeutics

October 12, 2025
Precision BioSciences Inc Stock

Precision BioSciences Stock Surges on Gene-Editing Breakthroughs

October 12, 2025
Nel ASA Stock

Hydrogen Sector’s Crossroads: Nel ASA Navigates Industry Retreat and Government Push

October 11, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Ebix Pursues Dual-Pronged Growth Strategy
  • Shareholder Confidence Boosts IGC Pharma’s Alzheimer’s Research
  • Allovir’s Corporate Metamorphosis: A New Beginning as Kalaris Therapeutics

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com